Marc A. Greenstein, DO, FACOS, of Advanced Urology in Atlanta, Georgia, discusses the findings from a recent real-world study demonstrating the overall survival benefit of apalutamide compared to enzalutamide in patients with metastatic castration-resistant prostate cancer (mCSPC). Dr. Greenstein talks about what implications this might have on clinical practice and payer coverage. ...
mCSPC
Advertisement
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Advertisement
Latest News
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.